A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (Q61773032)
Jump to navigation
Jump to search
article by Timothy F. Cloughesy et al published 20 May 2008 in Journal of Clinical Oncology
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) |
article by Timothy F. Cloughesy et al published 20 May 2008 in Journal of Clinical Oncology |
Statements
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (English)
0 references
20 May 2008
0 references
26
0 references
15_suppl
0 references
2010b-2010b
0 references